Keros Therapeutics, Inc. - 8-K Filing

Keros Therapeutics updates corporate presentation detailing rinvatercept (KER-065) clinical development and pipeline strategy. (Items: 7.01 Regulation FD Disclosure, 9.01 Financial Statements and Exhibits)

SEC EDGAR ·

Tickers: $KROS

Read the full article at SEC EDGAR

More Regulatory news